The market of Chinese medicines is swelling fast Enterprise should turn towards medicine " The foreign gentleman " Learn something

The market of Chinese medicines is swelling fast Enterprise should turn towards medicine " The foreign gentleman " Learn something
"Bayer enter China nearly 100 year, it can in another a century at China treat also. " Bayer first efficacious medical CEOAndreasFibig says. In 2009, this income from sales of Germany pharmacy enterprise is over 10,400 million euro, its main growth comes from Asian-Pacific area, especially China. Nobody dares to ignore " China's chance " . With process and economic affluence of senilization, the market of Chinese medicines is swelling fast. A report of McKinsey declares, regarding exceeding China where speed 20% increased as global pharmacy enterprises every year creates the captivating stage, and meanwhile, the growth rate of the American-European staple market is slowing down. This stretch of land pour into one after another transnational giant. The sci-tech park of Shanghai has even appeared " The medicine valley hotel " ,Specially in order that increasingly many western medicine enterprise staff offer the lunch around. What of AndreasFibig quite representative: "New developing market become Bayer already clever growth of medicine drive first, we must adopt the correct tactics in order to guarantee our status. " These tactics include introducing the research and development centre into China or bringing China within their global new medicines to release in the plan,etc.. Will it be February 2009, Bayer clever medicine drop 100 million into set up global research and development centre in Beijing first. Danish promise and Noda grow department's institute (SIBS) with Shanghai Set up cooperatively " The transforming research center of earlier stage of diabetes " . Novartis' pharmacy promises to invest 1 billion dollars too, before the end of 2015, build up a research and development centre in Shanghai. No doubt, the native medicine enterprise of China is unwilling to surrender submissively. However, compared with these transnational giants, China pharmacy enterprise is in status of about equal inferior position. 2008, only 41% of proportion that the top four account for. A lot of, small, scattered pattern makes most enterprises unable to become and research and develop the subject. The whole trade is unable to extend towards high side. "Though China is known as the world factory, is prominent short boards that medicines are made. " A researcher says. Innovation is the lifeblood of the pharmacy industry. Chinese Government permits and makes the western price for new medicine too, it is on the basis of approval and encouragement of innovation. However, it is a key of the native medicine enterprise of China to innovate exactly. The data reveal, China pharmacy enterprise has pitiably little input of research and development, its proportion of taking the income from sales of the whole year is generally fewer than 1%, outstanding enterprises seldom exceed 5% too. AndreasFibig says, Bayer has four major research and development centres, the whole world serves about 5900 staff that researched and developed, the input of research and development accounts for 15%~17% of the sales amount of that year. The outstanding medicine enterprise of China can't equate with these transnational giants either. Most of them depend on " a method is fresh, eat it all over it " ,Trump in the hand very little, and follow-up causes anxiety. There are the producers of some enterprises who become imitation medicine. At this year two Conferences, member of the CPPCC National Committee complains to the reporter, some medicine enterprises are even to model conscientiously out of patience, even abused the scamp work for the competition of the low price, " will do China pharmacy enterprise very much to do it in this way " . Another noteworthy phenomenon is, transnational pharmacy enterprises, through setting up research and development centre on one hand, do native pertinence to study, in order to continue keeping the advanced advantage; On the other hand permeate to general medicine through purchasing etc., in order to expand the market of low end. AndreasFibig say without mincing words, except Bayer orientates in the field of high medical demand through innovating, also set up the general medicine business platform, will expand brand non- patent medicine and regional products selectively. "This is the best times, it is the worst times too. Chinese medicine enterprise faces the unprecedented opportunity, face unprecedented enclosing and stopping up too. We can grow up in study fast, just like other manufacturing. " A Chinese medicine enterprise's boss says, " certainly this is difficult. "

|